Ganirelix Acetate Peptide Powder GMP Approved CAS NO.123246-29-7

The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reachease to 500kg with 3 main factory sites.

Ganirelix has potential applications in all conditions where reduced sex-steroid secretion is advantageous, including assisted reproduction protocols, advanced prostatic carcinoma, benign prostatic hyperplasia, uterine fibroids, and endometriosis. It has the potential therapeutic advantage over GnRH agonists of avoiding the initial stimulation of sex-steroid secretion. This will avoid the disease flare produced by agonists in prostatic carcinoma (Cook and Sheridan, 2000) and reduce the time over which it must be administered in assisted reproduction protocols.It is producing a similar pregnancy rate to that obtained using leuprorelin but with fewer injections and a shorter protocol.